Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma.

Velasco A, Pallares J, Santacana M, Gatius S, Fernandez M, Domingo M, Valls J, Yeramian A, Encinas M, Dolcet X, Matias-Guiu X.

Hum Pathol. 2011 Feb;42(2):185-93. doi: 10.1016/j.humpath.2010.08.001. Epub 2010 Nov 26.

PMID:
21111454
2.

Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma.

Pallarés J, Velasco A, Eritja N, Santacana M, Dolcet X, Cuatrecasas M, Palomar-Asenjo V, Catasús L, Prat J, Matias-Guiu X.

Mod Pathol. 2008 Jun;21(6):691-9. doi: 10.1038/modpathol.2008.38. Epub 2008 May 9.

3.

FGFR2 alterations in endometrial carcinoma.

Gatius S, Velasco A, Azueta A, Santacana M, Pallares J, Valls J, Dolcet X, Prat J, Matias-Guiu X.

Mod Pathol. 2011 Nov;24(11):1500-10. doi: 10.1038/modpathol.2011.110. Epub 2011 Jul 1.

4.

Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma.

Pallares J, Martínez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X.

J Pathol. 2004 Dec;204(5):569-77.

PMID:
15481028
5.

High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma.

Arafa M, Kridelka F, Mathias V, Vanbellinghen JF, Renard I, Foidart JM, Boniver J, Delvenne P.

Histopathology. 2008 Nov;53(5):525-32. doi: 10.1111/j.1365-2559.2008.03147.x. Epub 2008 Sep 8.

PMID:
18783461
6.

Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma.

Chan QK, Khoo US, Chan KY, Ngan HY, Li SS, Chiu PM, Man LS, Ip PP, Xue WC, Cheung AN.

J Mol Diagn. 2005 Feb;7(1):8-16.

7.

Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression.

Salvesen HB, Stefansson I, Kretzschmar EI, Gruber P, MacDonald ND, Ryan A, Jacobs IJ, Akslen LA, Das S.

Int J Oncol. 2004 Dec;25(6):1615-23.

PMID:
15547698
8.

Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3.

Pallares J, Martínez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X.

Int J Gynecol Pathol. 2005 Jul;24(3):247-53.

PMID:
15968200
9.

[Analysis of the status of DACH1 gene promoter methylation in endometrial carcinoma and its clinical significance].

Deng XC, Li SR, Zhang Q, Zhou CJ, Yang QF, Jiang J, Kong BH.

Zhonghua Fu Chan Ke Za Zhi. 2012 Apr;47(4):263-7. Chinese.

PMID:
22781112
10.

RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.

Pijnenborg JM, Dam-de Veen GC, Kisters N, Delvoux B, van Engeland M, Herman JG, Groothuis PG.

Ann Oncol. 2007 Mar;18(3):491-7. Epub 2006 Dec 14.

11.

Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability.

Kondo E, Furukawa T, Yoshinaga K, Kijima H, Semba S, Yatsuoka T, Yokoyama T, Fukushige S, Horii A.

Int J Oncol. 2000 Sep;17(3):535-41.

PMID:
10938395
12.

Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma.

Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B.

Cancer Invest. 2009 May;27(4):459-65. doi: 10.1080/07357900802620828.

PMID:
19160099
13.

Defective mismatch repair and the development of recurrent endometrial carcinoma.

Pijnenborg JM, Dam-de Veen GC, de Haan J, van Engeland M, Groothuis PG.

Gynecol Oncol. 2004 Aug;94(2):550-9.

PMID:
15297202
14.

Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.

Zou XP, Zhang B, Zhang XQ, Chen M, Cao J, Liu WJ.

Hum Pathol. 2009 Nov;40(11):1534-42. doi: 10.1016/j.humpath.2009.01.029. Epub 2009 Aug 19.

PMID:
19695681
15.

Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).

Niklinska W, Naumnik W, Sulewska A, Kozłowski M, Pankiewicz W, Milewski R.

Folia Histochem Cytobiol. 2009;47(2):275-80. doi: 10.2478/v10042-009-0091-2.

16.

RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.

Peters I, Rehmet K, Wilke N, Kuczyk MA, Hennenlotter J, Eilers T, Machtens S, Jonas U, Serth J.

Mol Cancer. 2007 Jul 16;6:49.

17.

Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis.

Liao X, Siu MK, Chan KY, Wong ES, Ngan HY, Chan QK, Li AS, Khoo US, Cheung AN.

Int J Cancer. 2008 Jul 15;123(2):296-302. doi: 10.1002/ijc.23494.

18.

Correlation between NDRG1 and PTEN expression in endometrial carcinoma.

Chen J, Li S, Yang Z, Lu G, Hu H.

Cancer Sci. 2008 Apr;99(4):706-10. doi: 10.1111/j.1349-7006.2008.00749.x.

19.

Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas.

Qian ZR, Sano T, Yoshimoto K, Yamada S, Ishizuka A, Mizusawa N, Horiguchi H, Hirokawa M, Asa SL.

Lab Invest. 2005 Apr;85(4):464-73.

20.

The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.

Furlan D, Carnevali I, Marcomini B, Cerutti R, Dainese E, Capella C, Riva C.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3329-36.

Items per page

Supplemental Content

Write to the Help Desk